Company profile: Citryll
1.1 - Company Overview
Company description
- Provider of pharmaceutical drugs targeting Neutrophil Extracellular Traps (NETs) to treat autoimmune and inflammatory diseases such as SLE, RA, vasculitis, and IPF. Offers CIT-013, a therapeutic antibody; conducts NETosis inhibition research to reduce auto-antigen release and clear pro-inflammatory NETs; advances clinical development with first-in-human and planned Phase 2a trials in RA and hidradenitis suppurativa; and pursues collaboration opportunities.
Products and services
- CIT-013: Target-specific therapeutic antibody that disrupts Neutrophil Extracellular Trap formation downstream of PAD-enzyme-catalyzed protein citrullination, aiming to treat SLE, rheumatoid arthritis, vasculitis, and idiopathic pulmonary fibrosis
- Clinical Development of CIT-013: Clinical-stage program executing first-in-human studies and planning Phase 2a proof-of-concept trials in rheumatoid arthritis and hidradenitis suppurativa patients
- NETosis Inhibition Research: Mechanism-based research to inhibit NETosis, decreasing auto-antigen release and promoting clearance of pro-inflammatory NETs to potentially disrupt the autoimmunity cycle downstream of PAD-catalyzed citrullination
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Citryll
Zura Bio
HQ: United States
Website
- Description: Provider of therapies for immune system disorders, advancing Phase 2 clinical programs including torudokimab (monoclonal antibody targeting IL33), ZB-168 (anti-IL7Rα monoclonal antibody inhibiting IL7/TSLP pathways with potential across T-cell–mediated diseases), and ZB-106 (tibulizumab), a bispecific antagonist of IL-17A and BAFF.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zura Bio company profile →
DST Diagnostische Systeme
HQ: Germany
Website
- Description: Provider of in-vitro diagnostic tests and products for allergy and food intolerance, developing, manufacturing and marketing laboratory and point-of-care systems. Offerings include sIgE rapid tests, LIA ALLERGY LINE kits, NutriSMART rapid tests, NutriLAB ELISA kits, over 600 allergen extracts for diagnostic use and IVD manufacturers, and laboratory services with reports and dietary recommendations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DST Diagnostische Systeme company profile →
NodThera
HQ: United Kingdom
Website
- Description: Provider of NLRP3 inflammasome inhibitor therapeutics targeting inflammatory and neuroinflammatory diseases, including brain-penetrant candidates. Lead asset NT-0796 is in Phase Ib/IIa for Parkinson’s disease and cardiovascular risk in obese patients; NT-0249 is optimized for low-dose chronic inflammatory therapy, with additional CNS and peripheral candidates under development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NodThera company profile →
Veloxis Pharmaceuticals
HQ: Denmark
Website
- Description: Provider of specialty pharmaceuticals for kidney transplant patients, focused on the development and commercialization of ENVARSUS XR, a once-daily extended-release tacrolimus tablet to prevent organ rejection and facilitate switching from immediate-release formulations, and VEL-101, an investigational immunosuppressant blocking CD28-mediated T cell activation while preserving CTLA-4 functions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veloxis Pharmaceuticals company profile →
Epiva
HQ: United States
Website
- Description: Provider of immuno-microbiome therapeutics, developing immunobiotic therapeutics through a platform from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epiva company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Citryll
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Citryll
2.2 - Growth funds investing in similar companies to Citryll
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Citryll
4.2 - Public trading comparable groups for Citryll
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →